The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an aminocarbonyl moiety； Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group； n is either 0 or 1； R<；SUP>；1 <；/SUP>；and R<；SUP>；2 <；/SUP>；are independently from each other is selected from the group consisting of hydrogen or C<；SUB>；1<；/SUB>；-C<；SUB>；6<；/SUB>；-alkyl； R<；SUP>；4 <；/SUP>；and R<；SUP>；5 <；/SUP>；are each independently from each other selected from the group consisting of H, hydroxy, C<；SUB>；1<；/SUB>；-C<；SUB>；6 <；/SUB>；alkyl, carboxy, C<；SUB>；1<；/SUB>；-C<；SUB>；6 <；/SUB>；alkoxy, C<；SUB>；1<；/SUB>；-C<；SUB>；3 <；/SUB>；alkyl carboxy, C<；SUB>；2<；/SUB>；-C<；SUB>；3 <；/SUB>；alkenyl carboxy, C<；SUB>；2<；/SUB>；-C<；SUB>；3 <；/SUB>；alkynyl carboxy, amino or R<；SUP>；4 <；/SUP>；and R<；SUP>；5 <；/SUP>；may form an unsaturated or saturated heterocyclic ring, whereby at least one of R<；SUP>；4 <；/SUP>；or R<；SUP>；5 <；/SUP>；is not a hydrogen or C<；SUB>；1<；/SUB>；-C<；SUB>；6 <；/SUB>；alkyl
